NCT03739905View on ClinicalTrials.gov

ExAblate Blood-Brain Barrier Opening for Treatment of Alzheimer's Disease

NAUnknownINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

December 6, 2018

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions
Alzheimer Disease
Interventions
DEVICE

Blood Brain Barrier (BBB) Disruption

Focal Ultrasound (FUS) involves the application of acoustic energy at low frequencies from over 1000 individual transducers into distinct targets to induce BBB disruption.

Trial Locations (1)

M4N 3M5

RECRUITING

Division of Neurosurgery, Sunnybrook Health Sciences Centre, Toronto

Sponsors

Lead Sponsor

InSightec
All Listed Sponsors
collaborator

Focused Ultrasound Foundation

OTHER

lead

InSightec

INDUSTRY

NCT03739905 - ExAblate Blood-Brain Barrier Opening for Treatment of Alzheimer's Disease | Biotech Hunter | Biotech Hunter